FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
about
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency.Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.[Metabolic disorders as paraneoplastic syndromes].Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies
P2860
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
FLORENCE: a randomized, double ...... intermediate to high TLS risk.
@en
FLORENCE: a randomized, double ...... intermediate to high TLS risk.
@nl
type
label
FLORENCE: a randomized, double ...... intermediate to high TLS risk.
@en
FLORENCE: a randomized, double ...... intermediate to high TLS risk.
@nl
prefLabel
FLORENCE: a randomized, double ...... intermediate to high TLS risk.
@en
FLORENCE: a randomized, double ...... intermediate to high TLS risk.
@nl
P2093
P2860
P50
P356
P1433
P1476
FLORENCE: a randomized, double ...... intermediate to high TLS risk.
@en
P2093
A Capriati
A S Pristupa
C Simonelli
FLORENCE Study Group
P2860
P304
P356
10.1093/ANNONC/MDV317
P50
P577
2015-07-27T00:00:00Z